A short social post says quitting drugs like semaglutide does not ruin metabolism, while pointing to research on weight regain afterward.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Retatrutide is still in clinical trials, but PharmaVoice reports Lilly is already going after a network of illicit sellers offering it online.
Tirzepatide alone reached 14.8% in the same trial. The catch: up to 27% of people on the combination quit over side effects, per the Motley Fool writeup.
Loading…